



**MEMORANDUM**

**To:** Donna E. Shalala, President

**From:** Stephen Sapp  
Chair, Faculty Senate

A handwritten signature in black ink that reads "Stephen Sapp".

**Date:** August 29, 2008

**Subject:** Faculty Senate Legislation #2008-03(B) – Proposal for the Establishment of the Dodson Interdisciplinary Immunotherapy Institute (DIII) at the Miller School of Medicine

\*\*\*\*\*

On August 27, 2008, the Senate voted to approve the proposal for the establishment of the Dodson Interdisciplinary Immunotherapy Institute (DIII) at the Miller School of Medicine as presented by Jennifer McCafferty-Cepero for five years and any extensions thereafter.<sup>1</sup>

The proposal is enclosed for your information.

The legislation is now forwarded to you for your action.

SS/rh

Enclosure (proposal)

cc: Thomas LeBlanc, Executive Vice President and Provost  
Pascal Goldschmidt, Sr. Vice President and Dean, Miller School of Medicine  
Jennifer McCafferty-Cepero, Presenter, Research Assistant Professor

[Please contact the Senate office to view this proposal.]

<sup>1</sup> C18.2.2 Other NAMED or TITLED ACADEMIC UNITS established under Bylaw 6.6 may be approved by the Faculty Senate and the President. For each such approved unit, the Executive Vice-President and Provost shall consult with the dean of the host school at five year intervals to determine whether the unit remains active and shall report to the Faculty Senate the names of those that should be disestablished.


C18.2.3 Periodic five year reviews may be conducted on all programs, centers, institutes and similar academic units as deemed appropriate by the Faculty Senate or the Executive Vice-President and Provost.

Faculty Senate  
1252 Memorial Drive, 325 Ashe Admin. Bldg.  
Coral Gables, Florida 33146

Phone: (305) 284-3721 • Fax: (305) 284-5515  
<http://www.miami.edu/FacultySenate>  
email: [facsen@miami.edu](mailto:facsen@miami.edu)

Faculty Senate Legislation #2008-03(B) – Proposal for the Establishment of the Dodson Interdisciplinary Immunotherapy Institute (DIII) at the Miller School of Medicine

**PRESIDENT'S RESPONSE**

APPROVED:  DATE: Sept 7 2008  
(President's Signature)

OFFICE OR INDIVIDUAL TO IMPLEMENT: DEAN PASCAL GOLDSCHMIDT

EFFECTIVE DATE OF LEGISLATION: IMMEDIATELY  
(if other than June 1 next following)

NOT APPROVED AND REFERRED TO: \_\_\_\_\_

REMARKS (IF NOT APPROVED): \_\_\_\_\_

[Please contact the Senate office to view this proposal.]



**MEMORANDUM**

**To:** Donna E. Shalala, President

**From:** Stephen Sapp  
Chair, Faculty Senate

A handwritten signature in black ink that reads "Stephen Sapp".

**Date:** August 29, 2008

**Subject:** Faculty Senate Legislation #2008-03(B) – Proposal for the Establishment of the Dodson Interdisciplinary Immunotherapy Institute (DIII) at the Miller School of Medicine

\*\*\*\*\*

On August 27, 2008, the Senate voted to approve the proposal for the establishment of the Dodson Interdisciplinary Immunotherapy Institute (DIII) at the Miller School of Medicine as presented by Jennifer McCafferty-Cepero for five years and any extensions thereafter.<sup>1</sup>

The proposal is enclosed for your information.

The legislation is now forwarded to you for your action.

SS/rh

Enclosure (proposal)

cc: Thomas LeBlanc, Executive Vice President and Provost  
Pascal Goldschmidt, Sr. Vice President and Dean, Miller School of Medicine  
Jennifer McCafferty-Cepero, Presenter, Research Assistant Professor


---

<sup>1</sup> C18.2.2 Other NAMED or TITLED ACADEMIC UNITS established under Bylaw 6.6 may be approved by the Faculty Senate and the President. For each such approved unit, the Executive Vice-President and Provost shall consult with the dean of the host school at five year intervals to determine whether the unit remains active and shall report to the Faculty Senate the names of those that should be disestablished.

C18.2.3 Periodic five year reviews may be conducted on all programs, centers, institutes and similar academic units as deemed appropriate by the Faculty Senate or the Executive Vice-President and Provost.

Faculty Senate Legislation #2008-03(B) – Proposal for the Establishment of the Dodson Interdisciplinary Immunotherapy Institute (DIII) at the Miller School of Medicine

**PRESIDENT'S RESPONSE**

APPROVED:  DATE: Sept 7 2008  
(President's Signature)

OFFICE OR INDIVIDUAL TO IMPLEMENT: DEAN PASCAL GOLDSCHMIDT

EFFECTIVE DATE OF LEGISLATION: IMMEDIATELY  
(if other than June 1 next following)

NOT APPROVED AND REFERRED TO: \_\_\_\_\_

REMARKS (IF NOT APPROVED): \_\_\_\_\_

**Proposal for the establishment of the  
The Dodson Interdisciplinary Immunotherapy Institute (DIII)  
at the University of Miami Miller School of Medicine**

This proposal seeks to formally establish the Dodson Interdisciplinary Immunotherapy Institute (DIII) at the University of Miami Miller School of Medicine. The Institute will be called the “Dodson Interdisciplinary Immunotherapy Institute.”

**I. BACKGROUND**

Therapies that harness the power of the immune system (immunotherapies) have revolutionized the way in which scientists and clinicians study and treat human diseases like cancer, AIDS, and diabetes and have dramatically improved the success of organ transplantation.

The development of immunotherapies requires a multidisciplinary approach involving expertise in fundamental and clinical immunology, molecular and cellular biology, infectious diseases, oncology, transplant, and endocrinology to name a few. The Miller School has an urgent need for an integrated, interdisciplinary institute that offers the expertise, infrastructure, and resources necessary to energize fundamental aspects of the science of immunotherapy and to advance translational research and speed new and novel immunotherapies to the clinic.

**II. MISSION**

The proposed Dodson Interdisciplinary Immunotherapy Institute (DIII) will develop immune-based treatments for cancer, infectious diseases, autoimmune diseases, and improve organ transplantation. The mission of the Institute is:

- I. To establish comprehensive & integrated programs to develop multi modality and high impact treatments that will benefit a large segment of the patient population
- II. To provide the infrastructure to facilitate the translation of preclinical proof-of-concept studies to advanced phase II indication-of-efficacy clinical testing
- III. To enhance the synergism and cross-fertilization among its programs by promoting common scientific activities and the development of core resources
- IV. To promote integration within the structure and mission of the UM Miller School of Medicine to enhance translational research throughout the Medical Center – train investigators and disseminate new treatment concepts and technologies and work closely with and establishing collaboration throughout the Medical Center, and beyond

**III. ORGANIZATION AND GOVERNANCE**

**Organization:**

**DIII Director:**

The Institute will be led by a Director. The Director will report to the Dean of the Miller School. The Institute Director represents the DIII in the Medical Center. He/She articulates the DIII vision and enhances the synergism and cross-fertilization of its Programs by promoting common scientific activities and the development of core resources, recruiting outstanding scientific teams from within and outside the UM community, and attracting external resources from government, private, and industrial, sources to support and expand the Institute activities. The Director will work to integrate the DIII within the structure and mission of the Miller School by promoting and nurturing two-way interactions with academic departments and other Centers and Institutes while being careful to not monopolize, or appear to monopolize, translational immunotherapy research at the Miller School. The Director will meet with Program Leaders regularly to chart the course of the Institute and its Programs, coordinate its complementary activities and address challenges as they arise.

#### **DIII Executive Committee:**

There will be an Executive Committee that meets quarterly to advise the Director on the various issues related to the Institute's operations. The Committee will also review applications for membership.

#### Charge of the Executive Committee

The DIII Executive Committee is an advisory board whose purpose is to assist the Director in the management, operations, and governance of the DIII including project prioritization and allocation of DIII resources.

#### Composition of the Executive Committee:

The Executive Committee will be comprised of the DIII Program Directors and other at large DIII members who are demonstrated leaders in immune-based treatments. The at-large members will be determined by a majority vote of the Executive Committee and will serve for three year terms. Terms of service are renewable at the discretion of the Executive Committee. The at-large DIII members will be University of Miami faculty members who have established research programs with a strong track record of interdisciplinary activities in the area of immune-based therapies and research.

The Executive Committee should reflect the interdisciplinary nature of the DIII and include representatives with expertise from the cancer, tolerance, and HIV&HCV fields.

At the discretion of the Executive Committee, other members of the University research community may be invited to attend the Executive Committee meetings.

#### Meetings of the Executive Committee:

The Executive Committee will be chaired by the DIII Director who will convene the Committee at least quarterly.

#### **DIII Advisory Committee:**

#### Charge of the Advisory Committee:

The DIII Advisory Committee is an external advisory group that evaluates the Institute's scientific progress, technological needs and assists the DIII Director in developing strategic plans for the future of the DIII.

#### Composition of the Advisory Committee:

The Advisory Committee is comprised of the DIII Director, the Dean of the Miller School (or the Dean's designee) and four external luminaries in immune-based therapy research. The DIII, in conjunction with the Dean (or designee) and the DIII Executive Committee, will identify and invite four internationally renowned senior scholars or industry leaders with a strong track record of interdisciplinary research and activities. The three year term of service for external luminaries is renewable at the discretion of the DIII Director, in conjunction with the Dean (or designee) and the DIII Executive Committee.

At the discretion of the External Advisory Committee, other members of the University research community may be invited to attend the External Advisory Committee meetings.

Meetings of the Advisory Committee:

The DIII Director will chair the Committee and convene annual meetings.

Programs:


The Institute will be organized around three interdisciplinary programs: Cancer, HIV&HCV, and Tolerance. Each program provides an integrated approach of preclinical studies and clinical trials to develop high impact treatments. The Programs will be led by Program Leaders. Program Leaders are chosen for their strategic vision, track record of creativity & productivity, flexibility to adjust and evolve programmatic goals, and the ability to foster an interactive and collegiate environment. The role of the Program Leaders will be to provide the strategic blueprint and necessary coordination to manage and integrate the various preclinical and clinical arms of the programs. Program Leaders will enjoy a high degree of autonomy in charting the course and management of their Programs.

**Cancer Program** - The Cancer Program will develop multi-pronged approaches including simpler and increasingly potent vaccination protocols, strategies to sustain the vaccine-induced immune response and methods to overcome the propensity of tumor cells to evade immune elimination, with increased emphasis on the latter.

**HIV/HCV Program** - The HIV/HCV Program will focus on the development of vaccination strategies which overcome the genetic instability and variability in combination with strategies to maintain the long term persistence of vaccine-generated antiviral immune response.

**Tolerance Program** - The Tolerance Program will develop complementary methods to induce autoantigen-specific tolerance by adoptive transfer of immune-suppressive population, tolerogenic vaccination and elimination of autoreactive immune cells.

### III. ORGANIZATIONAL CHART



### VI. MEMBERSHIP

Membership is open to all faculty members at the University of Miami. New members are recruited to help the establishment of the developing programs. Members are aligned with a particular program, although they may work in more than one concentration. All new members will receive information on the benefits and responsibilities of DIII membership.

Criteria for membership include a demonstrated research interest in immune-based treatments for cancer, infectious diseases, autoimmunity, and organ transplantation, and will agree to fulfill the responsibilities of DIII membership.

Interested faculty should send an email indicating a desire for membership to the DIII Director. Applicants should include a research statement and CV with current funding and publications information. Applications will be reviewed by the Executive Committee and awarded membership if appropriate. The Committee will meet yearly to review all membership. Should a faculty member be denied membership, he/she may submit a written appeal to the DIII Director. The DIII Director can grant the appeal or refer the matter to the Dean of the Miller School for final decision.

Benefits include eligibility to receive developmental funds for innovative ideas.

All members are expected to contribute to the mission of the DIII, have a willingness to work collaboratively on issues related to immunotherapy, actively participate in DIII activities and attend scheduled functions, and be willing to provide mentoring to junior faculty and other DIII members.

### III. SPACE

To function effectively, the members of the DIII do not have to be housed in extreme close proximity. Through meetings, seminars, and collaborative research projects, members will work in their respective spaces on the medical campus. Currently, the HIV/HCV program is housed on the 7<sup>th</sup> floor of the Batchelor Childrens'



Research Institute building. The Cancer program is located on the 2<sup>nd</sup> floor of the Pap building and the Tolerance program will be housed in the Diabetes Research Institute building and/or Highland building.

**IX. FUNDING SOURCES AND BUDGET PROJECTIONS.**

The DIII is being initially supported by a generous gift from the Dodson Foundation as well as by the Dean of the Miller School. These funds are to be spent over a five year period and will be used to create the infrastructure necessary to support DIII activities and resources as described above. All members are expected and encouraged to seek external funding for their research.

	<b>UM</b>	<b>Sponsored Activity</b>	<b>Gifts</b>
Year 1	1,000,000	250,000	2,000,000
Year 2	1,000,000	350,000	3,300,000
Year 3	500,000	450,000	3,300,000
Year 4	250,000	550,000	1,650,000
Year 5	250,000	700,000	1,650,000

## Appendix:

### **A. PROPOSED DIRECTOR**

Eli Gilboa PhD is the J. Enloe Dodson Professor of Microbiology & Immunology and the Co-director of the Tumor Immunobiology & Immunotherapy Program. Dr. Gilboa received his PhD in molecular biology at the Weizmann Institute, Rehovot, Israel, was an assistant professor in the Department of Molecular Biology at Princeton University, USA, from 1980-1986, and served as an associate member of the Memorial Sloan-Kettering Institute for Cancer Research Molecular Biology Program from 1986-1993. In 1993, Dr. Gilboa joined Duke University Medical Center as the Joseph and Dorothy Beard Professor of Experimental Surgery and Immunology and Director of the Center for Genetic and Cellular Therapies, overseeing the development and clinical implementation of novel gene- and cell-based therapies. In September 2006, Dr. Gilboa joined the Sylvester Comprehensive Cancer Center and Department of Microbiology & Immunology, Miller School of Medicine, University of Miami. His research interests include cellular immunology and immunotherapy using mRNA-transfected dendritic cells as therapeutic vaccines in the setting of cancer and infectious diseases. Dr. Gilboa is internationally recognized for his seminal contributions in the fields of gene therapy and cancer immunotherapy that helped shape these fields and remain widely used in the clinic and laboratory. He is also a scientific founder of Argos Therapeutics (formerly Merix Bioscience Inc.) and co-inventor of the core therapeutic vaccine technology of the company. Dr. Gilboa also co-founded Regado Inc. an RNA therapeutics company developing RNA aptamers to regulate coagulation.

### **B. POTENTIAL MEMBERS OF THE ADVISORY BOARD:**

Lee Nadler MD, Virginia and D.K. Ludwig Professor for Cancer Research, Department of Medicine, Harvard Medical School, Senior Vice President, Experimental Medicine, Dana-Farber Cancer Institute, Chief, Division of Medical Oncology, Brigham and Women's Hospital, Boston MA

Glen Dranoff MD, Associate Professor of Medicine, Harvard Medical School, Cambridge, MA  
Bruce Walker MD, Professor of Medicine, Partners for AIDS research, Mass General Hospital, Boston MA  
Carl June, MD, Professor, Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA

**MILLER**  
SCHOOL OF MEDICINE

To: Robyn Hardeman  
Secretary of the Faculty Senate

From: The Department of Microbiology and Immunology.

Date: May 15, 2008

Subject: Support for the Dodson Interdisciplinary Immunotherapy Institute

This memo is to request support from the Faculty Senate to approve the creation of the Dodson Interdisciplinary Immunotherapy Institute (DIII) at the Miller School of Medicine.

The establishment of the DIII will position the Miller School at the cutting edge of research related to the development of immunotherapies. Immunotherapies have not only revolutionized the way in which scientists and clinicians study and treat human diseases like cancer, AIDS, and diabetes but have dramatically improved the success of organ transplantation.

This interdisciplinary initiative is central to the success of such research as, by definition, immunotherapeutic development requires a multidisciplinary approach involving expertise in fundamental and clinical immunology, molecular and cellular biology, infectious diseases, oncology, transplant, and endocrinology to name a few. Importantly, the creation of the DIII would build an interdisciplinary home for immunotherapeutic development and research at the Miller School and create an organization around which to pool intellectual and technological resources – a considerable unmet need across the Miller School.

The DIII is an important and timely addition to the Miller School and the Department of Microbiology and Immunology and we are fully committed to its success. I offer the full cooperation of the Department of Microbiology and Immunology and fully endorse its creation.

Sincerely,




Eckhard R. Podack, M.D., Ph.D.

Sylvester Distinguished Professor and Chairman



To: Robyn Hardeman  
Secretary of the Faculty Senate

From: W. Jarrard Goodwin MD, FACS   
Director, Sylvester Comprehensive Cancer Center

Date: May 15, 2008

Subject: Support for the Dodson Interdisciplinary Immunotherapy Institute

I write in strong support of the creation of the Dodson Interdisciplinary Immunotherapy Institute (DIII) at the Miller School of Medicine

The establishment of the DIII developed as a part of the vision of recruiting Dr. Gilboa, which was shared by Dr. Podack, Dr. Ricordi, Dr. Pahwa, myself and other leaders in the Miller School of Medicine. The idea is to leverage work being done in multiple different types of disease, including cancer, AIDS, and diabetes, for the betterment of all. In my view, this is clearly happening.

The DIII is an important and timely addition to the Miller School and has been of great help in continuing to develop the Tumor Immunobiology Research Program of the Sylvester Comprehensive Cancer Center. I am committed to its success. I offer the full cooperation of UM/Sylvester and fully endorse its creation.



**MILLER**  
SCHOOL OF MEDICINE

To: Robyn Hardeman  
Secretary of the Faculty Senate

From: The Comprehensive AIDS Program

Date: May 15, 2008

Subject: Support for the Dodson Interdisciplinary Immunotherapy Institute

As Director of the Comprehensive AIDS Program for the University of Miami I strongly recommend approval for creation of the Dodson Interdisciplinary Immunotherapy Institute (DIII) at the Miller School of Medicine.

Over the past decade the field of medicine has embraced the fact that immune modulation will be critical in therapeutic interventions for most diseases. To remain at the cutting edge the Miller School of Medicine must keep step with the times and continue to build Institutes that support this vision. The DIII as proposed will place the University at the forefront in this effort.

Importantly, the multidisciplinary approach taken by the DIII will provide a means to engage researchers and clinicians from other Institutes and Departments to come together with a focus on immunotherapy. The DIII will be additive and supportive to the ongoing efforts. It will add to the canvas of research for the University that is integrative and supportive for all researchers/clinicians looking to expand their efforts from bench to bedside. Importantly, the creation of the DIII would build an interdisciplinary home for immunotherapeutic development and research at the Miller School and create an organization around which to pool intellectual and technological resources -- a considerable unmet need across the Miller School.

For the Comprehensive AIDS Program the DIII will fit well within our mission to enhance translational efforts in the HIV arena. The infrastructure and resources provided by the DIII will add to the efforts of the Comprehensive AIDS Program in a non-redundant manner thereby enhancing the platform for success in both research and intervention for a disease still in want of a cure. As such, the DIII is an important and timely addition to the Miller School and the Comprehensive AIDS Program and I am fully committed to its success. I offer the full cooperation of the Comprehensive AIDS Program and fully endorse the creation of the Dodson Interdisciplinary Immunotherapy Institute.

Sincerely,



Michael A. Kolber, PhD, MD  
Professor of Medicine  
Director, Comprehensive AIDS Program



**MILLER**  
SCHOOL OF MEDICINE

Pascal J. Goldschmidt, M.D., FACC  
Senior Vice President for Medical Affairs and Dean  
Chief Executive Officer  
University of Miami Health System

Memorandum

To: Robyn Hardeman  
Secretary of the Faculty Senate

From: Pascal Goldschmidt, M.D.  
Senior Vice President for Medical Affairs and Dean  
Miller School of Medicine

Date: August 4, 2008 *Pascal J. Goldschmidt*

Subject: Support for the Dodson Interdisciplinary Immunotherapy Institute

This memo is to document my strong support for the creation of the Dodson Interdisciplinary Immunotherapy Institute (DIII).

This interdisciplinary initiative is being created as part of a generous gift from the Dodson Foundation. The establishment of the DIII will position the Miller School at the cutting edge of research related to the development of immunotherapies. Immunotherapies have not only revolutionized the way in which scientists and clinicians study and treat human diseases like cancer, HIV/AIDS, and diabetes but have dramatically improved the success of organ transplantation.

The creation of the DIII is central to the success of immunotherapy related research at the Miller School as, by definition, immunotherapeutic development requires a multidisciplinary approach involving expertise in fundamental and clinical immunology, molecular and cellular biology, infectious diseases, oncology, transplant, and endocrinology to name a few. The DIII would build an interdisciplinary home for immunotherapeutic development and research at the Miller School and create an organization around which to share intellectual and technological resources – a goal of the Miller School. Importantly, the DIII is designed to limit redundancy by leveraging the technological and administrative infrastructures of other units including the Sylvester Cancer Center, the Department of Microbiology and Immunology and the Comprehensive AIDS program.

The DIII is an important and timely addition to the Miller School I am fully committed to its success. I offer the full cooperation of the School and fully endorse its creation.





DIABETES  
RESEARCH  
INSTITUTE

1450 NW 10 AVENUE  
MIAMI, FL 33136  
PHONE: 305 / 243-5376  
FAX: 305 / 243-4404

MAILING ADDRESS:  
P.O. BOX 016960 (R-134)  
MIAMI, FL 33101

To: Robyn Hardeman  
Secretary of the Faculty Senate

From: Camillo Ricordi, M.D.  
Scientific Director, Diabetes Research Institute

A handwritten signature in black ink, appearing to read "C. Ricordi", enclosed within a large, hand-drawn oval.

Date: August 18, 2008

Subject: Support for the Dodson Interdisciplinary Immunotherapy Institute

This memo is to request support from the Faculty Senate to approve the creation of the Dodson Interdisciplinary Immunotherapy Institute (DIII) at the Miller School of Medicine.

The establishment of the DIII will position the Miller School at the cutting edge of research related to the development of immunotherapies. Immunotherapies have not only revolutionized the way in which scientists and clinicians study and treat human diseases like cancer, AIDS, and diabetes but have dramatically improved the success of organ transplantation.

This interdisciplinary initiative is central to the success of such research as, by definition, immunotherapeutic development requires a multidisciplinary approach involving expertise in fundamental and clinical immunology, molecular and cellular biology, infectious diseases, oncology, transplant, and endocrinology to name a few. Importantly, the creation of the DIII would build an interdisciplinary home for immunotherapeutic development and research at the Miller School and create an organization around which to pool intellectual and technological resources – a considerable unmet need across the Miller School.

The DIII is an important and timely addition to the Miller School and the Diabetes Research Institute (DRI) and I are fully committed to its success. I offer the full cooperation of the DRI and fully endorse its creation.

UNIVERSITY  
OF MIAMI  
LEONARD M. MILLER  
SCHOOL OF MEDICINE



**MILLER**  
SCHOOL OF MEDICINE

**To:** Robyn Hardeman  
Secretary of the Faculty Senate

**From:** Andreas G. Tzakis, MD  
Miami Transplant Institute

**Date:** May 19, 2008

**Subject:** Support for the Dodson Interdisciplinary Immunotherapy Institute

This memo is to request support from the Faculty Senate to approve the creation of the Dodson Interdisciplinary Immunotherapy Institute (DIII) at the Miller School of Medicine.

The establishment of the DIII will position the Miller School at the cutting edge of research related to the development of immunotherapies. Immunotherapies have not only revolutionized the way in which scientists and clinicians study and treat human diseases like cancer, AIDS, and diabetes but have dramatically improved the success of organ transplantation.

This interdisciplinary initiative is central to the success of such research as, by definition, immunotherapeutic development requires a multidisciplinary approach involving expertise in fundamental and clinical immunology, molecular and cellular biology, infectious diseases, oncology, transplant, and endocrinology to name a few. Importantly, the creation of the DIII would build an interdisciplinary home for immunotherapeutic development and research at the Miller School and create an organization around which to pool intellectual and technological resources – a considerable unmet need across the Miller School.

The DIII is an important and timely addition to the Miller School and the Miami Transplant Institute and I am fully committed to its success. I offer the full cooperation of the Miami Transplant Institute and fully endorse its creation.





## Faculty Senate Office

---

**From:** Faculty Senate Office  
**Sent:** Monday, September 08, 2008 3:24 PM  
**To:** Goldschmidt, Pascal J.; 'McCafferty-Cepero, Jennifer'  
**Cc:** Iacino, Richard A.; Faculty Senate Office  
**Subject:** Legislation #2008-03(B)-proposal for the Establishment of the Dodson Interdisciplinary Immunotherapy Institute at the Miller School of Medicine  
**Attachments:** 2008 03.pdf

Attached is your copy of the legislation referenced above that has been approved by the President.

Regards,  
Robyn Hardeman

Faculty Senate Office  
University of Miami  
325 Ashe Administration Building  
1252 Memorial Drive  
Coral Gables, FL 33146  
(305) 284-3721  
Fax: (305) 284-5515  
[www.miami.edu/fs](http://www.miami.edu/fs)



**August 27, 2008**  
**Faculty Senate minutes**

The meeting, held in the BankUnited Center Hurricane 100 Room, Coral Gables Campus, opened at 3:30 p.m.

**CHAIR'S REMARKS**

In addition to the Chair's remarks included with the agenda, the Chair reported on the death of Sid Weisburd, formerly UM Registrar. He has written a letter to his family, as has been his custom with other families.

**PRESIDENT'S REMARKS**

The President explained that she expects an exciting year and that she has invited both Presidential candidates to come to campus; she has also invited some of their surrogates, including President Clinton, to talk about health care reform. She passed out a brochure of speakers who have been confirmed and encouraged faculty to invite their students. The list will be updated as more are confirmed.

She gave an update on the search processes, saying that because the perfect candidate was not identified for the Law School search, it was decided to go with a one-year acting dean, with the enthusiastic agreement of the Law School faculty. Paul Verkuil, a very distinguished legal scholar and former dean at both Cardoza and Tulane, agreed to take the position. She explained that it was unusual to go outside for an interim appointment but that it would have disrupted the teaching and curriculum of the Law School to select someone from inside. The search process is restarting with the creation of a new search committee for a permanent dean.

The Rosenstiel search committee has been appointed, with James Tien, Dean of the College of Engineering, as chair.

An outstanding freshman class has arrived and we have hit our target. We have increased the number of international students. Medical and Law School classes are among the best that we have ever had.

The University does not host funerals and had to turn down a request by Coral Gables leaders to host the funeral of the police chief who died recently. It was the beginning of school and we would have had to delay the start of classes to accommodate the funeral.

Facility improvements include renovating all of the Memorial classrooms, the Learning Center, and the residential college classrooms on the Gables campus, finishing the wet-lab at Medical, and planning for a research building at Rosenstiel.

President Shalala explained that we are tightening our belts to prepare for a very difficult economy and trying to put away reserves, for both the university and students.

She discussed the busing situation for faculty to football games and said that the Alumni Association will be looking into making arrangements. All spaces would have to be on a pre-paid basis. University buses will not be used.

She discussed the addition of bikes and Zipcars on campus as part of our "Green Initiative." Zipcars are available to all faculty and staff as well as students. All of the bikes have been sold, and more will be ordered.

There will be a new fund-raising campaign that will be announced, most probably in the spring. We are currently in the "silent phase," and a substantial gift has been promised to the Miller School.

The hospital numbers are looking all right, mostly because of the new faculty from Mount Sinai. So far people seem to be pleased. There will be an announcement about a new head of Bascom Palmer.

She entertained questions from the floor.

The Provost talked briefly about the University's US News rankings. UM moved from 52 to 51, passing Syracuse for the first time in our history. As we continue to improve, the progress will get slower and he explained the formula used and what our peers are doing. He entertained questions from the floor.

#### **STUDENT GOVERNMENT REPRESENTATIVES REMARKS**

The Senate Chair explained that he had had a productive meeting with Brandon Gross, Student Government President, and offered to allow the Student Government representatives to introduce themselves and briefly share with the Senate issues that they foresee for the coming year. Tia Dawkins-Hendricks and Sagar Patel explained that they have a good working relationship with the deans and wanted to extend that relationship to the faculty and urged members to come to the Student Government with any issues. They raised the issue of the new \$100 limit of photocopying for students, as opposed to the unlimited photocopying in the past. They also talked about the Student Government initiatives last year of selling bikes on campus and offering Zipcars.

#### **APPROVAL OF TODAY'S AGENDA**

The meeting agenda *passed unanimously*.

#### **APPROVAL OF MINUTES OF April 23, 2008**

The minutes of April 23, 2008, *passed unanimously*.

#### **INTRODUCTION OF KIRBY HOCUTT, DIRECTOR OF ATHLETICS**

The new director of athletics introduced himself and spoke briefly about his goals and vision for the athletic program. He invited the faculty to contact him directly with any issues concerning his department and entertained questions from the floor.

## **OTHER ANNOUNCEMENTS**

The Chair read a letter sent by President Emeritus Henry King Stanford in response to the Chair's letter wishing him a happy 92<sup>nd</sup> birthday.

## **2009 HEALTH CARE PLAN**

Joe Natoli, Cristina Elgarresta, and Jennifer Cohen summarized the 2009 Health Care Plan and the move from Humana to Aetna and handed out informational materials. They emphasized efforts to help employees stay healthy through numerous programs offered on campus. There will be many information sessions on each of the three campuses in October to make sure that everyone knows the differences among the four health plans that will be offered, which all include enhancements. Open enrollment is October 20 through November 7. They urged faculty to check the Aetna list of providers to see if their provider is on the list. If not, they asked that faculty send them the doctor's information so that the doctor can be added to the list. This plan is still pending final Board of Trustees approval. They entertained questions from the floor.

## **PROPOSAL FOR THE ESTABLISHMENT OF EDUCATOR FACULTY IN THE COLLEGE OF ENGINEERING**

Dr. Shihab Asfour, Associate Dean, College of Engineering, gave an overview of the proposal and pointed out that the changes requested by the General Welfare Committee were incorporated into the proposal. He entertained questions from the floor.

*The General Welfare Committee's recommendation to approve the proposal passed unanimously.*

## **PROPOSAL FOR THE ESTABLISHMENT OF THE UNIVERSITY OF MIAMI CENTER FOR COMPUTATIONAL SCIENCE**

Dr. Jennifer McCafferty-Cepero, Director, Research Program Development and Planning, explained that this proposal began circulating about a year ago and has been approved by all relevant faculty councils, ADPC, and GWC. She discussed the urgent unmet need at the University in the area of computational science. This proposed Center provides an interdisciplinary home for the organization and the coordination of computational resources. Because technology to support a super-computing environment is very expensive, rather than having requests come up repeatedly at various Schools and Colleges that require such services, the idea is to centralize the resources for hardware, software, and expertise to allow synergy to develop. This proposal is about capturing, storing, and analyzing large complex data sets and runs across disciplines. In a brief overview of the proposal, Dr. McCafferty-Cepero pointed out that there are 76 active collaborations coming from four participating schools taking place in the Center to date, 7 proposals have been funded, and another 15 have been submitted. She entertained questions from the floor.

*The General Welfare Committee's recommendation to approve the proposal passed unanimously.*

**PROPOSAL FOR THE ESTABLISHMENT OF THE DODSON INTERDISCIPLINARY IMMUNOTHERAPY INSTITUTE (DII) AT THE MILLER SCHOOL OF MEDICINE**

Dr. McCafferty-Cepero reviewed the proposal, which comes forward with the unanimous approval of the Miller School of Medicine faculty. The Institute comes directly from a very generous gift, which focuses on research in immunotherapy to develop vaccines, and it will collaborate with the Stem Cell Institute and Miami Institute of Genomics. A second program is focusing on HIV and HCV vaccination strategies. A third program relates to tolerance. She entertained questions.

*The General Welfare Committee's recommendation to approve the proposal passed unanimously.*

**PROPOSAL FOR THE ESTABLISHMENT OF THE MILLER SCHOOL OF MEDICINE COSMETIC MEDICAL AND RESEARCH INSTITUTE**

Dr. McCafferty-Cepero and Dr. Leslie Baumann, Professor of Clinical Dermatology and Cutaneous Surgery, presented the proposal and pointed out that this group grew up organically and is a self-sustaining enterprise that has received no money from the Miller School of Medicine. Once the group became aware of governance procedures regarding Institutes, they wanted to be in compliance with the Faculty Manual and therefore are presenting this proposal. The Institute consists of a small clinical practice group also involved in clinical trials, and they plan to pursue more NIH trials. They entertained questions from the floor.

*The General Welfare Committee's recommendation to approve the proposal passed unanimously.*

**PROPOSAL FOR AN INTERDEPARTMENTAL PhD PROGRAM IN HUMAN GENETICS AND GENOMICS**

Dr. William Scott, Miami Institute for Human Genomics, presented the proposal and pointed out that the proposal received approval from the Miller School Council, the Graduate Council, and the General Welfare Committee. It has been circulated to the basic science chairs and the associate dean's office as shown in the package of materials. The reason for the degree is to complement the initiatives that this University has pursued in this field over the last couple of years, creating a vibrant research environment on this campus as well as throughout south Florida. This requires that we train some of the professionals that we seek to employ and nurture.

*The General Welfare Committee's recommendation to approve the proposal passed unanimously.*

(Note: Because the agenda was running early, the following actions were taken out of order.)

**APPROVAL OF PROPOSED MEMBERSHIP ON**

- a) **COMMITTEE ON PROFESSIONAL CONDUCT**
- b) **FACULTY SENATE HEARING COMMITTEE**

*A motion was made to approve the proposed members. The motion was approved unanimously.*

**OTHER BUSINESS**

Lori Werner, Frost School of Music representative to the General Welfare Committee, has resigned from the GWC and the Frost School caucus recommends that Rachel Lebon replace her.

*Rachel Lebon was elected as the Frost School of Music General Welfare Committee representative.*

**PROPOSAL TO ALLOW MASTERS-PREPARED FACULTY IN THE DEPARTMENT OF PHYSICAL THERAPY AND THE SCHOOL OF NURSING AND HEALTH STUDIES TO PURSUE DOCTORAL STUDIES AT THEIR HOME SCHOOL/DEPARTMENT**

Dr. Victoria Mitrani, Senator and Professor of Nursing and Health Studies, and Dr. Sherrill Hayes, Senate First Vice Chair and Professor and Chair of Physical Therapy, reviewed the need for this action. They have incorporated advice from the General Welfare Committee and Graduate School Council. There are several provisions to help to deal with concerns raised, including a sunset clause that mandates expiration automatically in five years and a cap on the number of students per year (two per program per year); and any students who are admitted during the five years will of course be allowed to complete their degrees. Acceptance into the doctoral program will have to be approved by the unit and the dean of the Graduate School. Additional safeguards add another outside member to the dissertation committee, and the heads of the units (dean or chair) will not be allowed to serve on the committee. It was stressed that this is not legislation to change the Faculty Manual but encouragement to the dean of the Graduate School that in these particular instances and under these specific conditions, the Senate does not object to admission of masters-prepared faculty to doctoral programs in their own units. They entertained questions from the floor.

*The General Welfare Committee's recommendation to approve the proposal passed.*

**RECOMMENDATION TO CHANGE THE UNIVERSITY OF MIAMI'S REQUIREMENTS FOR LATIN HONORS**

Andrea Heuson, Chair of the 2007-08 Academic Standards Committee, presented the proposal, a revision of a recommendation brought forward to the committee last year to look at the procedure for granting Latin Honors to undergraduate students. The committee investigated and discovered that fewer than 1% of students who have the requisite grade point average graduate *summa cum laude* or *magna cum laude* because the University requires a thesis across all of the different schools. Although satisfying this requirement is easier in some schools and some departments, many students who qualify on the basis of GPA do not attain the highest Latin Honors because of the thesis. Based on suggestions from the General Welfare Committee, the Academic Standards Committee amended the proposal as presented today: 1) to include both a minimum GPA (the current levels) and a maximum percentage of awardees; 2) to encourage schools to develop their own versions of honors within their schools that are consistent with their disciplines and include a thesis, 3) to include Continuing Studies students with Arts and Sciences because Continuing Studies is so small, 4) to determine the values for the first year for Rosenstiel, which is only now starting an undergraduate program, by using Arts and Sciences levels, and 5) to have the Honors Program office administer Latin Honors based on numbers supplied by Enrollment Services. This proposal removes the requirement of a thesis to graduate with Latin Honors for new students, but it gives currently enrolled students the option to do the thesis because they are governed by the University bulletin in effect when they began at UM. Dr. Heuson entertained questions from the floor.

*The General Welfare Committee's recommendation to approve the proposal passed.*

**EXECUTIVE SESSION [Non-senate members were excused from the meeting at this point.]**  
**DISTINGUISHED FACULTY SCHOLAR AWARD RECOMMENDATION FROM THE**  
**GENERAL WELFARE COMMITTEE**  
[See separate Executive Session minutes.]

The meeting adjourned at 6:05 p.m.

Respectfully submitted,  
Robyn Hardeman  
Secretary of the Faculty Senate

## Faculty Senate Office

---

**From:** Faculty Senate Office  
**Sent:** Tuesday, September 09, 2008 9:47 AM  
**To:** Berg, Shelton G.; Brown, Otis B.; Cabrera, Jose M.; Carpintero, Yvette M.; Fontellio, Dawn J; Garcia, Cecilia; Glemaud, Rose-Kellie; Goldschmidt, Pascal J.; Grogg, Sam; Halleran, Michael Ros; Kahn, Barbara; Lepisto, Catherine; Paul Verkuil (pverduil@law.miami.edu); Peragallo, Nilda P; Perez, Danette; Plater-Zyberk, Elizabeth M.; Prilleltensky, Isaac; Ripoll, Blanca Ileana; Robitaille, Magaly; Roshaven, Jennifer Ann; Rowand, Michele M; Ruiz, Odalis Agueda; Scandura, Teresa Anne; Stadmire, Dawn Renee; Tien, James M.; Verkuil, Paul R; Walker, William  
**Cc:** Sapp, Stephen; Markowitz, Elizabeth Paz; Faculty Senate Office  
**Subject:** Approved Faculty Senate legislation  
**Attachments:** 2008 02.pdf; 2008 03.pdf; 2008 04.pdf; 2008 05.pdf; 2008 06.pdf

Below is a list of the legislation recently approved by the President as shown on the Faculty Senate web site. (To view the legislation, just click on the highlighted legislation number.) The complete legislation with proposals is attached for your information.

Legislation [#2008-01\(B\)](#)-Proposal for the Establishment of Educator Faculty in the College of Engineering

Legislation [#2008-02\(B\)](#)-Proposal for the Establishment of the University of Miami Center for Computational Science

Legislation [#2008-03\(B\)](#)-Proposal for the Establishment of the Dodson Interdisciplinary Immunotherapy

Legislation [#2008-04\(B\)](#)-Proposal for the Establishment of the Miller School of Medicine Cosmetic Medical and Research Institute

Legislation [#2008-05\(B\)](#)-Proposal for the Establishment of an Interdepartmental PhD Program in Human Genetics and Genomics at the Miller School of Medicine (pending Board of Trustees approval)

Legislation [#2008-06\(B\)](#)-Recommendation to Change the University of Miami's Requirements for Latin Honors

Please let me know if you have any questions.

Regards,

Robyn Hardeman

Faculty Senate Office  
University of Miami  
325 Ashe Administration Building  
1252 Memorial Drive  
Coral Gables, FL 33146  
(305) 284-3721  
Fax: (305) 284-5515  
[www.miami.edu/fs](http://www.miami.edu/fs)



# FACULTY SENATE MEETING AGENDA

Hurricane 100 Room-BankUnited Center

August 27, 2008, 3:30 P.M.

[CLICK HERE](#) to print all of the agenda materials EXCEPT for [item B3](#).

NOTE: You must print this item separately.

	<b>Approx. Time</b>
<b>A. <u>Introductory Matters</u></b>	
A1. Chair's remarks	3:30
A2. President's remarks	3:35
A3. Student Government Representative's remarks	3:50
A4. Approval of today's agenda	3:55
A5. <u>Approval of Faculty Senate meeting minutes of April 23, 2008</u>	4:00
A6. Introduction of Kirby Hocutt, Director of Athletics	4:05
A7. Other announcements	4:20
<b>B. <u>General Matters</u></b>	
B1. 2009 Health Care Plan – INFORMATION ITEM ONLY - J. Natoli, C. Elgarresta, J. Cohen	4:30
B2. <u># Proposal for the establishment of Educator Faculty in the College of Engineering – S. Asfour</u>	4:50
B3. <u># Proposal for the establishment of the University of Miami Center for Computational Science - J. McCafferty-Cepero</u>	5:05
B4. <u># Proposal for the establishment of the Dodson Interdisciplinary Immunotherapy Institute (DIII) at the Miller School of Medicine – J. McCafferty-Cepero</u>	5:20
B5. <u># Proposal for the establishment of the Miller School of Medicine Cosmetic Medical and Research Institute – J. McCafferty-Cepero, L. Baumann, B. Chernow</u>	5:30
B6. <u># Proposal for an Interdepartmental PhD Program in Human Genetics and Genomics – B. Scott</u>	5:45
B7. <u># Recommendation to change the University of Miami's requirements for Latin Honors – A. Heuson</u>	5:55
B8. <u># Proposal to Allow Masters Prepared Faculty in the Department of Physical Therapy and the School of Nursing and Health Studies to Pursue Doctoral Studies at their Home School/Department – S. Hayes, V. Mitrani</u>	6:10
B9. #Approval of proposed membership on: a) <u>Committee on Professional Conduct</u> b) <u>Faculty Hearing Committee</u>	6:25
B10. <u>#Faculty Senate Standing Committee Appointments - INFORMATION ITEM</u>	
<b>C. <u>Other Business</u></b>	6:30
<b>D. <u>Executive Session</u></b>	
D1. Distinguished Faculty Scholar Award recommendations from the General Welfare Committee – J. Prospero	6:35
<b>E. <u>Adjournment</u></b>	

#related material

**Proposal for the establishment of the  
The Dodson Interdisciplinary Immunotherapy Institute (DIII)  
at the University of Miami Miller School of Medicine**

This proposal seeks to formally establish the Dodson Interdisciplinary Immunotherapy Institute (DIII) at the University of Miami Miller School of Medicine. The Institute will be called the "Dodson Interdisciplinary Immunotherapy Institute."

**I. BACKGROUND**

Therapies that harness the power of the immune system (immunotherapies) have revolutionized the way in which scientists and clinicians study and treat human diseases like cancer, AIDS, and diabetes and have dramatically improved the success of organ transplantation.

The development of immunotherapies requires a multidisciplinary approach involving expertise in fundamental and clinical immunology, molecular and cellular biology, infectious diseases, oncology, transplant, and endocrinology to name a few. The Miller School has an urgent need for an integrated, interdisciplinary institute that offers the expertise, infrastructure, and resources necessary to energize fundamental aspects of the science of immunotherapy and to advance translational research and speed new and novel immunotherapies to the clinic.

**II. MISSION**

The proposed Dodson Interdisciplinary Immunotherapy Institute (DIII) will develop immune-based treatments for cancer, infectious diseases, autoimmune diseases, and improve organ transplantation. The mission of the Institute is:

- I. To establish comprehensive & integrated programs to develop multi modality and high impact treatments that will benefit a large segment of the patient population
- II. To provide the infrastructure to facilitate the translation of preclinical proof-of-concept studies to advanced phase II indication-of-efficacy clinical testing
- III. To enhance the synergism and cross-fertilization among its programs by promoting common scientific activities and the development of core resources
- IV. To promote integration within the structure and mission of the UM Miller School of Medicine to enhance translational research throughout the Medical Center – train investigators and disseminate new treatment concepts and technologies and work closely with and establishing collaboration throughout the Medical Center, and beyond

**III. ORGANIZATION AND GOVERNANCE**

**Organization:**

**DIII Director:**

The Institute will be led by a Director. The Director will report to the Dean of the Miller School. The Institute Director represents the DIII in the Medical Center. He/She articulates the DIII vision and enhances the synergism and cross-fertilization of its Programs by promoting common scientific activities and the development of core resources, recruiting outstanding scientific teams from within and outside the UM community, and attracting external resources from government, private, and industrial, sources to support and expand the Institute activities. The Director will work to integrate the DIII within the structure and mission of the Miller School by promoting and nurturing two-way interactions with academic departments and other Centers and Institutes while being careful to not monopolize, or appear to monopolize, translational immunotherapy research at the Miller School. The Director will meet with Program Leaders regularly to chart the course of the Institute and its Programs, coordinate its complementary activities and address challenges as they arise.

#### **DIII Executive Committee:**

There will be an Executive Committee that meets quarterly to advise the Director on the various issues related to the Institute's operations. The Committee will also review applications for membership.

#### Charge of the Executive Committee

The DIII Executive Committee is an advisory board whose purpose is to assist the Director in the management, operations, and governance of the DIII including project prioritization and allocation of DIII resources.

#### Composition of the Executive Committee:

The Executive Committee will be comprised of the DIII Program Directors and other at large DIII members who are demonstrated leaders in immune-based treatments. The at-large members will be determined by a majority vote of the Executive Committee and will serve for three year terms. Terms of service are renewable at the discretion of the Executive Committee. The at-large DIII members will be University of Miami faculty members who have established research programs with a strong track record of interdisciplinary activities in the area of immune-based therapies and research.

The Executive Committee should reflect the interdisciplinary nature of the DIII and include representatives with expertise from the cancer, tolerance, and HIV&HCV fields.

At the discretion of the Executive Committee, other members of the University research community may be invited to attend the Executive Committee meetings.

#### Meetings of the Executive Committee:

The Executive Committee will be chaired by the DIII Director who will convene the Committee at least quarterly.

#### **DIII Advisory Committee:**

#### Charge of the Advisory Committee:

The DIII Advisory Committee is an external advisory group that evaluates the Institute's scientific progress, technological needs and assists the DIII Director in developing strategic plans for the future of the DIII.

#### Composition of the Advisory Committee:

The Advisory Committee is comprised of the DIII Director, the Dean of the Miller School (or the Dean's designee) and four external luminaries in immune-based therapy research. The DIII, in conjunction with the Dean (or designee) and the DIII Executive Committee, will identify and invite four internationally renowned senior scholars or industry leaders with a strong track record of interdisciplinary research and activities. The three year term of service for external luminaries is renewable at the discretion of the DIII Director, in conjunction with the Dean (or designee) and the DIII Executive Committee.

At the discretion of the External Advisory Committee, other members of the University research community may be invited to attend the External Advisory Committee meetings.

Meetings of the Advisory Committee:

The DIII Director will chair the Committee and convene annual meetings.

Programs:


The Institute will be organized around three interdisciplinary programs: Cancer, HIV&HCV, and Tolerance. Each program provides an integrated approach of preclinical studies and clinical trials to develop high impact treatments. The Programs will be led by Program Leaders. Program Leaders are chosen for their strategic vision, track record of creativity & productivity, flexibility to adjust and evolve programmatic goals, and the ability to foster an interactive and collegiate environment. The role of the Program Leaders will be to provide the strategic blueprint and necessary coordination to manage and integrate the various preclinical and clinical arms of the programs. Program Leaders will enjoy a high degree of autonomy in charting the course and management of their Programs.

**Cancer Program** - The Cancer Program will develop multi-pronged approaches including simpler and increasingly potent vaccination protocols, strategies to sustain the vaccine-induced immune response and methods to overcome the propensity of tumor cells to evade immune elimination, with increased emphasis on the latter.

**HIV/HCV Program** - The HIV/HCV Program will focus on the development of vaccination strategies which overcome the genetic instability and variability in combination with strategies to maintain the long term persistence of vaccine-generated antiviral immune response.

**Tolerance Program** - The Tolerance Program will develop complementary methods to induce autoantigen-specific tolerance by adoptive transfer of immune-suppressive population, tolerogenic vaccination and elimination of autoreactive immune cells.

**III. ORGANIZATIONAL CHART**



**VI. MEMBERSHIP**

Membership is open to all faculty members at the University of Miami. New members are recruited to help the establishment of the developing programs. Members are aligned with a particular program, although they may work in more than one concentration. All new members will receive information on the benefits and responsibilities of DIII membership.

Criteria for membership include a demonstrated research interest in immune-based treatments for cancer, infectious diseases, autoimmunity, and organ transplantation, and will agree to fulfill the responsibilities of DIII membership.

Interested faculty should send an email indicating a desire for membership to the DIII Director. Applicants should include a research statement and CV with current funding and publications information. Applications will be reviewed by the Executive Committee and awarded membership if appropriate. The Committee will meet yearly to review all membership. Should a faculty member be denied membership, he/she may submit a written appeal to the DIII Director. The DIII Director can grant the appeal or refer the matter to the Dean of the Miller School for final decision.

Benefits include eligibility to receive developmental funds for innovative ideas.

All members are expected to contribute to the mission of the DIII, have a willingness to work collaboratively on issues related to immunotherapy, actively participate in DIII activities and attend scheduled functions, and be willing to provide mentoring to junior faculty and other DIII members.

**III. SPACE**

To function effectively, the members of the DIII do not have to be housed in extreme close proximity. Through meetings, seminars, and collaborative research projects, members will work in their respective spaces on the medical campus. Currently, the HIV/HCV program is housed on the 7<sup>th</sup> floor of the Batchelor Childrens'

Research Institute building. The Cancer program is located on the 2<sup>nd</sup> floor of the Pap building and the Tolerance program will be housed in the Diabetes Research Institute building and/or Highland building.

**IX. FUNDING SOURCES AND BUDGET PROJECTIONS.**

The DIII is being initially supported by a generous gift from the Dodson Foundation as well as by the Dean of the Miller School. These funds are to be spent over a five year period and will be used to create the infrastructure necessary to support DIII activities and resources as described above. All members are expected and encouraged to seek external funding for their research.

	UM	Sponsored Activity	Gifts
Year 1	1,000,000	250,000	2,000,000
Year 2	1,000,000	350,000	3,300,000
Year 3	500,000	450,000	3,300,000
Year 4	250,000	550,000	1,650,000
Year 5	250,000	700,000	1,650,000

Appendix:

**A. PROPOSED DIRECTOR**

Eli Gilboa PhD is the J. Enloe Dodson Professor of Microbiology & Immunology and the Co-director of the Tumor Immunobiology & Immunotherapy Program. Dr. Gilboa received his PhD in molecular biology at the Weizmann Institute, Rehovot, Israel, was an assistant professor in the Department of Molecular Biology at Princeton University, USA, from 1980-1986, and served as an associate member of the Memorial Sloan-Kettering Institute for Cancer Research Molecular Biology Program from 1986-1993. In 1993, Dr. Gilboa joined Duke University Medical Center as the Joseph and Dorothy Beard Professor of Experimental Surgery and Immunology and Director of the Center for Genetic and Cellular Therapies, overseeing the development and clinical implementation of novel gene- and cell-based therapies. In September 2006, Dr. Gilboa joined the Sylvester Comprehensive Cancer Center and Department of Microbiology & Immunology, Miller School of Medicine, University of Miami. His research interests include cellular immunology and immunotherapy using mRNA-transfected dendritic cells as therapeutic vaccines in the setting of cancer and infectious diseases. Dr. Gilboa is internationally recognized for his seminal contributions in the fields of gene therapy and cancer immunotherapy that helped shape these fields and remain widely used in the clinic and laboratory. He is also a scientific founder of Argos Therapeutics (formerly Merix Bioscience Inc.) and co-inventor of the core therapeutic vaccine technology of the company. Dr. Gilboa also co-founded Regado Inc. an RNA therapeutics company developing RNA aptamers to regulate coagulation.

**B. POTENTIAL MEMBERS OF THE ADVISORY BOARD:**

Lee Nadler MD, Virginia and D.K. Ludwig Professor for Cancer Research, Department of Medicine, Harvard Medical School, Senior Vice President, Experimental Medicine, Dana-Farber Cancer Institute, Chief, Division of Medical Oncology, Brigham and Women's Hospital, Boston MA

Glen Dranoff MD, Associate Professor of Medicine, Harvard Medical School, Cambridge, MA  
Bruce Walker MD, Professor of Medicine, Partners for AIDS research, Mass General Hospital, Boston MA  
Carl June, MD, Professor, Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA

**MILLER**  
SCHOOL OF MEDICINE

"Dodson Interdisciplinary Immunotherapy Institute"  
8-27-08 FS agenda item  
Page 7 of 12

To: Robyn Hardeman  
Secretary of the Faculty Senate

From: The Department of Microbiology and Immunology.

Date: May 15, 2008

Subject: Support for the Dodson Interdisciplinary Immunotherapy Institute


This memo is to request support from the Faculty Senate to approve the creation of the Dodson Interdisciplinary Immunotherapy Institute (DIII) at the Miller School of Medicine.

The establishment of the DIII will position the Miller School at the cutting edge of research related to the development of immunotherapies. Immunotherapies have not only revolutionized the way in which scientists and clinicians study and treat human diseases like cancer, AIDS, and diabetes but have dramatically improved the success of organ transplantation.

This interdisciplinary initiative is central to the success of such research as, by definition, immunotherapeutic development requires a multidisciplinary approach involving expertise in fundamental and clinical immunology, molecular and cellular biology, infectious diseases, oncology, transplant, and endocrinology to name a few. Importantly, the creation of the DIII would build an interdisciplinary home for immunotherapeutic development and research at the Miller School and create an organization around which to pool intellectual and technological resources – a considerable unmet need across the Miller School.

The DIII is an important and timely addition to the Miller School and the Department of Microbiology and Immunology and we are fully committed to its success. I offer the full cooperation of the Department of Microbiology and Immunology and fully endorse its creation.

Sincerely,



Eckhard R. Podack, M.D., Ph.D.

Sylvester Distinguished Professor and Chairman





To: Robyn Hardeman  
Secretary of the Faculty Senate

From: W. Jarrard Goodwin MD, FACS *WJG*  
Director, Sylvester Comprehensive Cancer Center

Date: May 15, 2008

Subject: Support for the Dodson Interdisciplinary Immunotherapy Institute

I write in strong support of the creation of the Dodson Interdisciplinary Immunotherapy Institute (DIII) at the Miller School of Medicine

The establishment of the DIII developed as a part of the vision of recruiting Dr. Gilboa, which was shared by Dr. Podack, Dr. Ricordi, Dr. Pahwa, myself and other leaders in the Miller School of Medicine. The idea is to leverage work being done in multiple different types of disease, including cancer, AIDS, and diabetes, for the betterment of all. In my view, this is clearly happening.

The DIII is an important and timely addition to the Miller School and has been of great help in continuing to develop the Tumor Immunobiology Research Program of the Sylvester Comprehensive Cancer Center. I am committed to its success. I offer the full cooperation of UM/Sylvester and fully endorse its creation.



**MILLER**  
SCHOOL OF MEDICINE

"Dodson Interdisciplinary Immunotherapy Institute"  
8-27-08 FS agenda item  
Page 9 of 12

To: Robyn Hardeman  
Secretary of the Faculty Senate

From: The Comprehensive AIDS Program

Date: May 15, 2008

Subject: Support for the Dodson Interdisciplinary Immunotherapy Institute

As Director of the Comprehensive AIDS Program for the University of Miami I strongly recommend approval for creation of the Dodson Interdisciplinary Immunotherapy Institute (DIII) at the Miller School of Medicine.

Over the past decade the field of medicine has embraced the fact that immune modulation will be critical in therapeutic interventions for most diseases. To remain at the cutting edge the Miller School of Medicine must keep step with the times and continue to build Institutes that support this vision. The DIII as proposed will place the University at the forefront in this effort.

Importantly, the multidisciplinary approach taken by the DIII will provide a means to engage researchers and clinicians from other Institutes and Departments to come together with a focus on immunotherapy. The DIII will be additive and supportive to the ongoing efforts. It will add to the canvas of research for the University that is integrative and supportive for all researchers/clinicians looking to expand their efforts from bench to bedside. Importantly, the creation of the DIII would build an interdisciplinary home for immunotherapeutic development and research at the Miller School and create an organization around which to pool intellectual and technological resources – a considerable unmet need across the Miller School.

For the Comprehensive AIDS Program the DIII will fit well within our mission to enhance translational efforts in the HIV arena. The infrastructure and resources provided by the DIII will add to the efforts of the Comprehensive AIDS Program in a non-redundant manner thereby enhancing the platform for success in both research and intervention for a disease still in want of a cure. As such, the DIII is an important and timely addition to the Miller School and the Comprehensive AIDS Program and I am fully committed to its success. I offer the full cooperation of the Comprehensive AIDS Program and fully endorse the creation of the Dodson Interdisciplinary Immunotherapy Institute.

Sincerely,



Michael A. Kolber, PhD, MD  
Professor of Medicine  
Director, Comprehensive AIDS Program



**MILLER**  
SCHOOL OF MEDICINE

Pascal J. Goldschmidt, M.D., FACC  
Senior Vice President for Medical Affairs and Dean  
Chief Executive Officer  
University of Miami Health System

Memorandum

To: Robyn Hardeman  
Secretary of the Faculty Senate

From: Pascal Goldschmidt, M.D.  
Senior Vice President for Medical Affairs and Dean  
Miller School of Medicine

Date: August 4, 2008 *Pascal J. Goldschmidt*

Subject: Support for the Dodson Interdisciplinary Immunotherapy Institute

This memo is to document my strong support for the creation of the Dodson Interdisciplinary Immunotherapy Institute (DIII).

This interdisciplinary initiative is being created as part of a generous gift from the Dodson Foundation. The establishment of the DIII will position the Miller School at the cutting edge of research related to the development of immunotherapies. Immunotherapies have not only revolutionized the way in which scientists and clinicians study and treat human diseases like cancer, HIV/AIDS, and diabetes but have dramatically improved the success of organ transplantation.

The creation of the DIII is central to the success of immunotherapy related research at the Miller School as, by definition, immunotherapeutic development requires a multidisciplinary approach involving expertise in fundamental and clinical immunology, molecular and cellular biology, infectious diseases, oncology, transplant, and endocrinology to name a few. The DIII would build an interdisciplinary home for immunotherapeutic development and research at the Miller School and create an organization around which to share intellectual and technological resources – a goal of the Miller School. Importantly, the DIII is designed to limit redundancy by leveraging the technological and administrative infrastructures of other units including the Sylvester Cancer Center, the Department of Microbiology and Immunology and the Comprehensive AIDS program.

The DIII is an important and timely addition to the Miller School I am fully committed to its success. I offer the full cooperation of the School and fully endorse its creation.





DIABETES  
RESEARCH  
INSTITUTE

1450 NW 19 AVENUE  
MIAMI FL 33125  
PHONE: 305 243-5376  
FAX: 305 243-4404

MAILING ADDRESS:  
PO BOX 069608-350  
MIAMI FL 33101

To: Robyn Hardeman  
Secretary of the Faculty Senate

From: Camillo Ricordi, M.D.  
Scientific Director, Diabetes Research Institute

Date: August 18, 2008

Subject: Support for the Dodson Interdisciplinary Immunotherapy Institute

A handwritten signature in black ink, appearing to read "Camillo Ricordi", written over a horizontal line.

This memo is to request support from the Faculty Senate to approve the creation of the Dodson Interdisciplinary Immunotherapy Institute (DIII) at the Miller School of Medicine.

The establishment of the DIII will position the Miller School at the cutting edge of research related to the development of immunotherapies. Immunotherapies have not only revolutionized the way in which scientists and clinicians study and treat human diseases like cancer, AIDS, and diabetes but have dramatically improved the success of organ transplantation.

This interdisciplinary initiative is central to the success of such research as, by definition, immunotherapeutic development requires a multidisciplinary approach involving expertise in fundamental and clinical immunology, molecular and cellular biology, infectious diseases, oncology, transplant, and endocrinology to name a few. Importantly, the creation of the DIII would build an interdisciplinary home for immunotherapeutic development and research at the Miller School and create an organization around which to pool intellectual and technological resources -- a considerable unmet need across the Miller School.

The DIII is an important and timely addition to the Miller School and the Diabetes Research Institute (DRI) and I are fully committed to its success. I offer the full cooperation of the DRI and fully endorse its creation.

UNIVERSITY  
OF MIAMI  
LEONARD M. MILLER  
SCHOOL OF MEDICINE



**MILLER**  
SCHOOL OF MEDICINE

"Dodson Interdisciplinary Immunotherapy Institute"  
8-27-08 FS agenda item  
Page 12 of 12

**To:** Robyn Hardeman  
Secretary of the Faculty Senate

**From:** Andreas G. Tzakis, MD  
Miami Transplant Institute

**Date:** May 19, 2008

**Subject:** Support for the Dodson Interdisciplinary Immunotherapy Institute

This memo is to request support from the Faculty Senate to approve the creation of the Dodson Interdisciplinary Immunotherapy Institute (DIII) at the Miller School of Medicine.

The establishment of the DIII will position the Miller School at the cutting edge of research related to the development of immunotherapies. Immunotherapies have not only revolutionized the way in which scientists and clinicians study and treat human diseases like cancer, AIDS, and diabetes but have dramatically improved the success of organ transplantation.

This interdisciplinary initiative is central to the success of such research as, by definition, immunotherapeutic development requires a multidisciplinary approach involving expertise in fundamental and clinical immunology, molecular and cellular biology, infectious diseases, oncology, transplant, and endocrinology to name a few. Importantly, the creation of the DIII would build an interdisciplinary home for immunotherapeutic development and research at the Miller School and create an organization around which to pool intellectual and technological resources – a considerable unmet need across the Miller School.

The DIII is an important and timely addition to the Miller School and the Miami Transplant Institute and I am fully committed to its success. I offer the full cooperation of the Miami Transplant Institute and fully endorse its creation.



**General Welfare Committee**  
**August 20, 2008**  
**3:30 p.m.**  
**5<sup>TH</sup> Floor Conference Room**  
**Fred C. and Helen Donn Flipse Building**

[CLICK HERE](#) to print the total agenda package

1. Chair's remarks (3:30)
2. # Review of Faculty Senate Meeting minutes of April 23, 2008 (3:35)
3. # Proposal for the establishment of Educator Faculty in the College of Engineering - (3:40) – J. Tien
4. # Proposal for the establishment of the University of Miami Center for Computational Science - (3:55) - J. McCafferty-Cepero
5. # Proposal for the establishment of the Dodson Interdisciplinary Immunotherapy Institute (DIII) at the Miller School of Medicine – (4:10) - J. McCafferty-Cepero
6. # Proposal for the establishment of the Miller School of Medicine Cosmetic Medical and Research Institute – (4:25) – J. McCafferty-Cepero
7. # Proposal for an Interdepartmental PhD Program in Human Genetics and Genomics – (4:40) – B. Scott
8. 2009 Health Care Plan – (4:55) – C. Elgarresta, J. Cohen
9. Distinguished Faculty Award Recommendation – (5:10) – M. Ginsberg
10. # Recommendation to change the University of Miami's requirements for Latin Honors – (5:15) - A. Heuson
11. # Proposal to Allow Masters Prepared Faculty in the Department of Physical Therapy and the School of Nursing and Health Studies to Pursue Doctoral Studies at their Home School/Department – (5:30) - V. Mitrani

\*\*\*\*\*

# related material included

**Proposal for the establishment of the  
The Dodson Interdisciplinary Immunotherapy Institute (DIII)  
at the University of Miami Miller School of Medicine**

This proposal seeks to formally establish the Dodson Interdisciplinary Immunotherapy Institute (DIII) at the University of Miami Miller School of Medicine. The Institute will be called the "Dodson Interdisciplinary Immunotherapy Institute."

**I. BACKGROUND**

Therapies that harness the power of the immune system (immunotherapies) have revolutionized the way in which scientists and clinicians study and treat human diseases like cancer, AIDS, and diabetes and have dramatically improved the success of organ transplantation.

The development of immunotherapies requires a multidisciplinary approach involving expertise in fundamental and clinical immunology, molecular and cellular biology, infectious diseases, oncology, transplant, and endocrinology to name a few. The Miller School has an urgent need for an integrated, interdisciplinary institute that offers the expertise, infrastructure, and resources necessary to energize fundamental aspects of the science of immunotherapy and to advance translational research and speed new and novel immunotherapies to the clinic.

**II. MISSION**

The proposed Dodson Interdisciplinary Immunotherapy Institute (DIII) will develop immune-based treatments for cancer, infectious diseases, autoimmune diseases, and improve organ transplantation. The mission of the Institute is:

- I. To establish comprehensive & integrated programs to develop multi modality and high impact treatments that will benefit a large segment of the patient population
- II. To provide the infrastructure to facilitate the translation of preclinical proof-of-concept studies to advanced phase II indication-of-efficacy clinical testing
- III. To enhance the synergism and cross-fertilization among its programs by promoting common scientific activities and the development of core resources
- IV. To promote integration within the structure and mission of the UM Miller School of Medicine to enhance translational research throughout the Medical Center – train investigators and disseminate new treatment concepts and technologies and work closely with and establishing collaboration throughout the Medical Center, and beyond

**III. ORGANIZATION AND GOVERNANCE**

**Organization:**

**DIII Director:**

The Institute will be led by a Director. The Director will report to the Dean of the Miller School. The Institute Director represents the DIII in the Medical Center. He/She articulates the DIII vision and enhances the synergism and cross-fertilization of its Programs by promoting common scientific activities and the development of core resources, recruiting outstanding scientific teams from within and outside the UM community, and attracting external resources from government, private, and industrial, sources to support and expand the Institute activities. The Director will work to integrate the DIII within the structure and mission of the Miller School by promoting and nurturing two-way interactions with academic departments and other Centers and Institutes while being careful to not monopolize, or appear to monopolize, translational immunotherapy research at the Miller School. The Director will meet with Program Leaders regularly to chart the course of the Institute and its Programs, coordinate its complementary activities and address challenges as they arise.

#### **DIII Executive Committee:**

There will be an Executive Committee that meets quarterly to advise the Director on the various issues related to the Institute's operations. The Committee will also review applications for membership.

#### Charge of the Executive Committee

The DIII Executive Committee is an advisory board whose purpose is to assist the Director in the management, operations, and governance of the DIII including project prioritization and allocation of DIII resources.

#### Composition of the Executive Committee:

The Executive Committee will be comprised of the DIII Program Directors and other at large DIII members who are demonstrated leaders in immune-based treatments. The at-large members will be determined by a majority vote of the Executive Committee and will serve for three year terms. Terms of service are renewable at the discretion of the Executive Committee. The at-large DIII members will be University of Miami faculty members who have established research programs with a strong track record of interdisciplinary activities in the area of immune-based therapies and research.

The Executive Committee should reflect the interdisciplinary nature of the DIII and include representatives with expertise from the cancer, tolerance, and HIV&HCV fields.

At the discretion of the Executive Committee, other members of the University research community may be invited to attend the Executive Committee meetings.

#### Meetings of the Executive Committee:

The Executive Committee will be chaired by the DIII Director who will convene the Committee at least quarterly.

#### **DIII Advisory Committee:**

#### Charge of the Advisory Committee:

The DIII Advisory Committee is an external advisory group that evaluates the Institute's scientific progress, technological needs and assists the DIII Director in developing strategic plans for the future of the DIII.

#### Composition of the Advisory Committee:



The Advisory Committee is comprised of the DIII Director, the Dean of the Miller School (or the Dean's designee) and four external luminaries in immune-based therapy research. The DIII, in conjunction with the Dean (or designee) and the DIII Executive Committee, will identify and invite four internationally renowned senior scholars or industry leaders with a strong track record of interdisciplinary research and activities. The three year term of service for external luminaries is renewable at the discretion of the DIII Director, in conjunction with the Dean (or designee) and the DIII Executive Committee.

At the discretion of the External Advisory Committee, other members of the University research community may be invited to attend the External Advisory Committee meetings.

Meetings of the Advisory Committee:

The DIII Director will chair the Committee and convene annual meetings.

Programs:


The Institute will be organized around three interdisciplinary programs: Cancer, HIV&HCV, and Tolerance. Each program provides an integrated approach of preclinical studies and clinical trials to develop high impact treatments. The Programs will be led by Program Leaders. Program Leaders are chosen for their strategic vision, track record of creativity & productivity, flexibility to adjust and evolve programmatic goals, and the ability to foster an interactive and collegiate environment. The role of the Program Leaders will be to provide the strategic blueprint and necessary coordination to manage and integrate the various preclinical and clinical arms of the programs. Program Leaders will enjoy a high degree of autonomy in charting the course and management of their Programs.

**Cancer Program** - The Cancer Program will develop multi-pronged approaches including simpler and increasingly potent vaccination protocols, strategies to sustain the vaccine-induced immune response and methods to overcome the propensity of tumor cells to evade immune elimination, with increased emphasis on the latter.

**HIV/HCV Program** - The HIV/HCV Program will focus on the development of vaccination strategies which overcome the genetic instability and variability in combination with strategies to maintain the long term persistence of vaccine-generated antiviral immune response.

**Tolerance Program** - The Tolerance Program will develop complementary methods to induce autoantigen-specific tolerance by adoptive transfer of immune-suppressive population, tolerogenic vaccination and elimination of autoreactive immune cells.

### III. ORGANIZATIONAL CHART



### VI. MEMBERSHIP

Membership is open to all faculty members at the University of Miami. New members are recruited to help the establishment of the developing programs. Members are aligned with a particular program, although they may work in more than one concentration. All new members will receive information on the benefits and responsibilities of DIII membership.

Criteria for membership include a demonstrated research interest in immune-based treatments for cancer, infectious diseases, autoimmunity, and organ transplantation, and will agree to fulfill the responsibilities of DIII membership.

Interested faculty should send an email indicating a desire for membership to the DIII Director. Applicants should include a research statement and CV with current funding and publications information. Applications will be reviewed by the Executive Committee and awarded membership if appropriate. The Committee will meet yearly to review all membership. Should a faculty member be denied membership, he/she may submit a written appeal to the DIII Director. The DIII Director can grant the appeal or refer the matter to the Dean of the Miller School for final decision.

Benefits include eligibility to receive developmental funds for innovative ideas.

All members are expected to contribute to the mission of the DIII, have a willingness to work collaboratively on issues related to immunotherapy, actively participate in DIII activities and attend scheduled functions, and be willing to provide mentoring to junior faculty and other DIII members.

### III. SPACE

To function effectively, the members of the DIII do not have to be housed in extreme close proximity. Through meetings, seminars, and collaborative research projects, members will work in their respective spaces on the medical campus. Currently, the HIV/HCV program is housed on the 7<sup>th</sup> floor of the Batchelor Childrens'

Research Institute building. The Cancer program is located on the 2<sup>nd</sup> floor of the Pap building and the Tolerance program will be housed in the Diabetes Research Institute building and/or Highland building.

**IX. FUNDING SOURCES AND BUDGET PROJECTIONS.**

The DIII is being initially supported by a generous gift from the Dodson Foundation as well as by the Dean of the Miller School. These funds are to be spent over a five year period and will be used to create the infrastructure necessary to support DIII activities and resources as described above. All members are expected and encouraged to seek external funding for their research.

	UM	Sponsored Activity	Gifts
Year 1	1,000,000	250,000	2,000,000
Year 2	1,000,000	350,000	3,300,000
Year 3	500,000	450,000	3,300,000
Year 4	250,000	550,000	1,650,000
Year 5	250,000	700,000	1,650,000

**Appendix:**

**A. PROPOSED DIRECTOR**

Eli Gilboa PhD is the J. Enloe Dodson Professor of Microbiology & Immunology and the Co-director of the Tumor Immunobiology & Immunotherapy Program. Dr. Gilboa received his PhD in molecular biology at the Weizmann Institute, Rehovot, Israel, was an assistant professor in the Department of Molecular Biology at Princeton University, USA, from 1980-1986, and served as an associate member of the Memorial Sloan-Kettering Institute for Cancer Research Molecular Biology Program from 1986-1993. In 1993, Dr. Gilboa joined Duke University Medical Center as the Joseph and Dorothy Beard Professor of Experimental Surgery and Immunology and Director of the Center for Genetic and Cellular Therapies, overseeing the development and clinical implementation of novel gene- and cell-based therapies. In September 2006, Dr. Gilboa joined the Sylvester Comprehensive Cancer Center and Department of Microbiology & Immunology, Miller School of Medicine, University of Miami. His research interests include cellular immunology and immunotherapy using mRNA-transfected dendritic cells as therapeutic vaccines in the setting of cancer and infectious diseases. Dr. Gilboa is internationally recognized for his seminal contributions in the fields of gene therapy and cancer immunotherapy that helped shape these fields and remain widely used in the clinic and laboratory. He is also a scientific founder of Argos Therapeutics (formerly Merix Bioscience Inc.) and co-inventor of the core therapeutic vaccine technology of the company. Dr. Gilboa also co-founded Regado Inc. an RNA therapeutics company developing RNA aptamers to regulate coagulation.

**B. POTENTIAL MEMBERS OF THE ADVISORY BOARD:**

Lee Nadler MD, Virginia and D.K. Ludwig Professor for Cancer Research, Department of Medicine, Harvard Medical School, Senior Vice President, Experimental Medicine, Dana-Farber Cancer Institute, Chief, Division of Medical Oncology, Brigham and Women's Hospital, Boston MA

Glen Dranoff MD, Associate Professor of Medicine, Harvard Medical School, Cambridge, MA  
Bruce Walker MD, Professor of Medicine, Partners for AIDS research, Mass General Hospital, Boston MA  
Carl June, MD, Professor, Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA

**MILLER**  
SCHOOL OF MEDICINE

"The Dodson Interdisciplinary Immunotherapy Institute"

8-20-08 GWC agenda item

Page 7 of 10

To: Robyn Hardeman  
Secretary of the Faculty Senate

From: The Department of Microbiology and Immunology.

Date: May 15, 2008

Subject: Support for the Dodson Interdisciplinary Immunotherapy Institute


This memo is to request support from the Faculty Senate to approve the creation of the Dodson Interdisciplinary Immunotherapy Institute (DIII) at the Miller School of Medicine.

The establishment of the DIII will position the Miller School at the cutting edge of research related to the development of immunotherapies. Immunotherapies have not only revolutionized the way in which scientists and clinicians study and treat human diseases like cancer, AIDS, and diabetes but have dramatically improved the success of organ transplantation.

This interdisciplinary initiative is central to the success of such research as, by definition, immunotherapeutic development requires a multidisciplinary approach involving expertise in fundamental and clinical immunology, molecular and cellular biology, infectious diseases, oncology, transplant, and endocrinology to name a few. Importantly, the creation of the DIII would build an interdisciplinary home for immunotherapeutic development and research at the Miller School and create an organization around which to pool intellectual and technological resources – a considerable unmet need across the Miller School.

The DIII is an important and timely addition to the Miller School and the Department of Microbiology and Immunology and we are fully committed to its success. I offer the full cooperation of the Department of Microbiology and Immunology and fully endorse its creation.

Sincerely,




Eckhard R. Podack, M.D., Ph.D.

Sylvester Distinguished Professor and Chairman



Department of Microbiology and Immunology • Leonard M. Miller School of Medicine  
Post Office Box 016960 (R-138) • Miami, Florida 33101  
Location: 1600 NW 10th Avenue, 3045a RMSB • Miami, Florida 33136  
305-243-6655 • Fax: 305-243-4623 • <http://chroma.med.miami.edu/micro>

To: Robyn Hardeman  
Secretary of the Faculty Senate

From: W. Jarrard Goodwin MD, FACS   
Director, Sylvester Comprehensive Cancer Center

Date: May 15, 2008

Subject: Support for the Dodson Interdisciplinary Immunotherapy Institute

I write in strong support of the creation of the Dodson Interdisciplinary Immunotherapy Institute (DIII) at the Miller School of Medicine

The establishment of the DIII developed as a part of the vision of recruiting Dr. Gilboa, which was shared by Dr. Podack, Dr. Ricordi, Dr. Pahwa, myself and other leaders in the Miller School of Medicine. The idea is to leverage work being done in multiple different types of disease, including cancer, AIDS, and diabetes, for the betterment of all. In my view, this is clearly happening.

The DIII is an important and timely addition to the Miller School and has been of great help in continuing to develop the Tumor Immunobiology Research Program of the Sylvester Comprehensive Cancer Center. I am committed to its success. I offer the full cooperation of UM/Sylvester and fully endorse its creation.



**MILLER**  
SCHOOL OF MEDICINE

"The Dodson Interdisciplinary Immunotherapy Institute"  
8-20-08 GWC agenda item  
Page 9 of 10

To: Robyn Hardeman  
Secretary of the Faculty Senate

From: The Comprehensive AIDS Program

Date: May 15, 2008

Subject: Support for the Dodson Interdisciplinary Immunotherapy Institute

As Director of the Comprehensive AIDS Program for the University of Miami I strongly recommend approval for creation of the Dodson Interdisciplinary Immunotherapy Institute (DIII) at the Miller School of Medicine.

Over the past decade the field of medicine has embraced the fact that immune modulation will be critical in therapeutic interventions for most diseases. To remain at the cutting edge the Miller School of Medicine must keep step with the times and continue to build Institutes that support this vision. The DIII as proposed will place the University at the forefront in this effort.

Importantly, the multidisciplinary approach taken by the DIII will provide a means to engage researchers and clinicians from other Institutes and Departments to come together with a focus on immunotherapy. The DIII will be additive and supportive to the ongoing efforts. It will add to the canvas of research for the University that is integrative and supportive for all researchers/clinicians looking to expand their efforts from bench to bedside. Importantly, the creation of the DIII would build an interdisciplinary home for immunotherapeutic development and research at the Miller School and create an organization around which to pool intellectual and technological resources -- a considerable unmet need across the Miller School.

For the Comprehensive AIDS Program the DIII will fit well within our mission to enhance translational efforts in the HIV arena. The infrastructure and resources provided by the DIII will add to the efforts of the Comprehensive AIDS Program in a non-redundant manner thereby enhancing the platform for success in both research and intervention for a disease still in want of a cure. As such, the DIII is an important and timely addition to the Miller School and the Comprehensive AIDS Program and I am fully committed to its success. I offer the full cooperation of the Comprehensive AIDS Program and fully endorse the creation of the Dodson Interdisciplinary Immunotherapy Institute.

Sincerely,



Michael A. Kolber, PhD, MD  
Professor of Medicine  
Director, Comprehensive AIDS Program



**MILLER**  
SCHOOL OF MEDICINE

Pascal J. Goldschmidt, M.D., FACC  
Senior Vice President for Medical Affairs and Dean  
Chief Executive Officer  
University of Miami Health System

Memorandum

To: Robyn Hardeman  
Secretary of the Faculty Senate

From: Pascal Goldschmidt, M.D.  
Senior Vice President for Medical Affairs and Dean  
Miller School of Medicine

Date: August 4, 2008 *Pascal J. Goldschmidt*

Subject: Support for the Dodson Interdisciplinary Immunotherapy Institute

This memo is to document my strong support for the creation of the Dodson Interdisciplinary Immunotherapy Institute (DIII).

This interdisciplinary initiative is being created as part of a generous gift from the Dodson Foundation. The establishment of the DIII will position the Miller School at the cutting edge of research related to the development of immunotherapies. Immunotherapies have not only revolutionized the way in which scientists and clinicians study and treat human diseases like cancer, HIV/AIDS, and diabetes but have dramatically improved the success of organ transplantation.

The creation of the DIII is central to the success of immunotherapy related research at the Miller School as, by definition, immunotherapeutic development requires a multidisciplinary approach involving expertise in fundamental and clinical immunology, molecular and cellular biology, infectious diseases, oncology, transplant, and endocrinology to name a few. The DIII would build an interdisciplinary home for immunotherapeutic development and research at the Miller School and create an organization around which to share intellectual and technological resources – a goal of the Miller School. Importantly, the DIII is designed to limit redundancy by leveraging the technological and administrative infrastructures of other units including the Sylvester Cancer Center, the Department of Microbiology and Immunology and the Comprehensive AIDS program.

The DIII is an important and timely addition to the Miller School I am fully committed to its success. I offer the full cooperation of the School and fully endorse its creation.







MEMORANDUM

logged in E/I book 9/9/08 RH  
proposed director:  
Eli Gilboa

To: Donna E. Shalala, President

From: Stephen Sapp  
Chair, Faculty Senate *Stephen Sapp*

Date: August 29, 2008

Subject: Faculty Senate Legislation #2008-03(B) – Proposal for the Establishment of the Dodson Interdisciplinary Immunotherapy Institute (DIII) at the Miller School of Medicine

\*\*\*\*\*

On August 27, 2008, the Senate voted to approve the proposal for the establishment of the Dodson Interdisciplinary Immunotherapy Institute (DIII) at the Miller School of Medicine as presented by Jennifer McCafferty-Cepero for five years and any extensions thereafter.<sup>1</sup>

The proposal is enclosed for your information.

The legislation is now forwarded to you for your action.

SS/rh

Enclosure (proposal)

cc: Thomas LeBlanc, Executive Vice President and Provost  
Pascal Goldschmidt, Sr. Vice President and Dean, Miller School of Medicine  
Jennifer McCafferty-Cepero, Presenter, Research Assistant Professor

<sup>1</sup> C18.2.2 Other NAMED or TITLED ACADEMIC UNITS established under Bylaw 6.6 may be approved by the Faculty Senate and the President. For each such approved unit, the Executive Vice-President and Provost shall consult with the dean of the host school at five year intervals to determine whether the unit remains active and shall report to the Faculty Senate the names of those that should be disestablished.

C18.2.3 Periodic five year reviews may be conducted on all programs, centers, institutes and similar academic units as deemed appropriate by the Faculty Senate or the Executive Vice-President and Provost.